Central nervous system (CNS) disorders remain difficult to treat because many pharmacologically active molecules do not achieve adequate exposure in the brain. The blood–brain barrier (BBB), blood-cerebrospinal fluid (CSF) barrier, efflux transporters, extracellular matrix, and local clearance mechanisms impose different constraints according to the target compartment and administration route. Nanocarriers can protect unstable payloads, alter pharmacokinetics, and support receptor-mediated or local delivery, but the same properties that promote transport can also increase immune recognition, tissue retention, and neurotoxicity. This review critically examines how nanoparticles (NPs) size, surface charge, composition, degradability, ligand density, and release kinetics should be matched to intravenous, intranasal, intrathecal, intracranial, and oral administration. Rather than treating these routes as interchangeable, we compare the barriers encountered by each route, the payloads for which it is best suited, and the experimental conditions that limit interpretation of reported brain uptake. Particular attention is given to the weak correspondence between many rodent efficacy studies and human delivery constraints, including protein-corona formation after systemic dosing, species differences in BBB and nasal anatomy, limited parenchymal penetration from cerebrospinal fluid, and the procedural risks of direct administration. The resulting route-specific framework is intended to support application-driven formulation design and more informative preclinical evaluation of CNS nanomedicines.

Highways to the Brain: Nanoformulations for the Treatment of Central Nervous System Pathologies / Romano, E., Moulton, C., Vanti, G., Grifoni, L., Cremonesi, G., De Filippis, L., Bilia, A.R., Tasciotti, E.. - In: PHARMACEUTICS. - ISSN 1999-4923. - ELETTRONICO. - 18:(2026), pp. 1472.0-1472.0. [10.3390/pharmaceutics18111472]

Highways to the Brain: Nanoformulations for the Treatment of Central Nervous System Pathologies

Vanti, Giulia;Grifoni, Lucia;Bilia, Anna Rita;
2026

Abstract

Central nervous system (CNS) disorders remain difficult to treat because many pharmacologically active molecules do not achieve adequate exposure in the brain. The blood–brain barrier (BBB), blood-cerebrospinal fluid (CSF) barrier, efflux transporters, extracellular matrix, and local clearance mechanisms impose different constraints according to the target compartment and administration route. Nanocarriers can protect unstable payloads, alter pharmacokinetics, and support receptor-mediated or local delivery, but the same properties that promote transport can also increase immune recognition, tissue retention, and neurotoxicity. This review critically examines how nanoparticles (NPs) size, surface charge, composition, degradability, ligand density, and release kinetics should be matched to intravenous, intranasal, intrathecal, intracranial, and oral administration. Rather than treating these routes as interchangeable, we compare the barriers encountered by each route, the payloads for which it is best suited, and the experimental conditions that limit interpretation of reported brain uptake. Particular attention is given to the weak correspondence between many rodent efficacy studies and human delivery constraints, including protein-corona formation after systemic dosing, species differences in BBB and nasal anatomy, limited parenchymal penetration from cerebrospinal fluid, and the procedural risks of direct administration. The resulting route-specific framework is intended to support application-driven formulation design and more informative preclinical evaluation of CNS nanomedicines.
2026
Romano, Eugenia; Moulton, Chantalle; Vanti, Giulia; Grifoni, Lucia; Cremonesi, Giada; De Filippis, Lidia; Bilia, Anna Rita; Tasciotti, Ennio
File in questo prodotto:
File Dimensione Formato  
2_pharmaceutics-18-01472.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Creative commons
Dimensione 3.58 MB
Formato Adobe PDF
3.58 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1501413
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact